"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
DEMSER (metyrosine) is indicated in the treatment of patients with pheochromocytoma for:
- Preoperative preparation of patients for surgery
- Management of patients when surgery is contraindicated
- Chronic treatment of patients with malignant pheochromocytoma.
DEMSER (metyrosine) is not recommended for the control of essential hypertension.
DOSAGE AND ADMINISTRATION
The recommended initial dosage of DEMSER (metyrosine) for adults and children 12 years of age and older is 250 mg orally four times daily. This may be increased by 250 mg to 500 mg every day to a maximum of 4.0 g/day in divided doses. When used for preoperative preparation, the optimally effective dosage of DEMSER (metyrosine) should be given for at least five to seven days.
Optimally effective dosages of DEMSER (metyrosine) usually are between 2.0 and 3.0 g/day, and the dose should be titrated by monitoring clinical symptoms and catecholamine excretion. In patients who are hypertensive, dosage should be titrated to achieve normalization of blood pressure and control of clinical symptoms. In patients who are usually normotensive, dosage should be titrated to the amount that will reduce urinary metanephrines and/or vanillylmandelic acid by 50 percent or more.
If patients are not adequately controlled by the use of DEMSER (metyrosine) , an alpha-adrenergic blocking agent (phenoxybenzamine) should be added.
Use of DEMSER (metyrosine) in children under 12 years of age has been limited and a dosage schedule for this age group cannot be given.
No. 3355 — Capsules DEMSER (metyrosine) , 250 mg, are opaque, two-toned blue capsules coded MSD 690 on one side and DEMSER (metyrosine) on the other. They are supplied as follows:
NDC 0006-0690-68 bottles of 100.
MERCK AND CO., INC., Whitehouse Station, NJ 08889,USA. Issued April 2002. FDA Rev date:
Last reviewed on RxList: 11/20/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Demser Information
Demser - User Reviews
Demser User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.